Licensing status

Publication and contact information


Lung cancer

Epidermal growth factor receptor (EGFR)

In vitro and mouse studies identified 2,8-dianilino-purine compounds that could help treat EGFR-mutant lung cancer. In vitro, a lead compound inhibited EGFR with an IC50 value of 4 nM. In mice with human lung cancer cells, the compound decreased tumor growth compared with an equivalent dose of the EGFR inhibitor Iressa gefitinib. Next steps could include additional preclinical pharmacokinetic studies.
AstraZeneca plc markets Iressa in the EU to treat non-small cell lung cancer (NSCLC).

SciBX 5(45); doi:10.1038/scibx.2012.1180
Published online Nov. 15, 2012

Patent application filed; unavailable for licensing

Yang, S.-Y. et al. J. Med. Chem.; published online Nov. 1, 2012;
Contact: Sheng-Yong Yang, Sichuan University, Sichuan, China